Item 2.02.  Results of Operations and Financial Condition.
On January 10, 2022, AtriCure, Inc. ("AtriCure" or the "Company") issued a press
release announcing its preliminary financial results for the fourth quarter and
full year ended December 31, 2021. A copy of the press release is furnished as
Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.
Item 7.01.  Regulation FD Disclosure.
During the week of January 10, 2022 the Company is holding meetings with
investors discussing, among other topics, an overview of the Company's business
and growth strategy. A copy of the investor presentation, which is available at
www.atricure.com, is furnished as Exhibit 99.2 to this Form 8-K and is
incorporated herein by reference.
Information in the presentation contains forward-looking statements regarding
future events and performance of the Company. All such forward-looking
statements are based largely on the Company's experience and perception of
current conditions, trends, expected future developments and other factors, and
on management's expectations, and are subject to risks and uncertainties that
could cause actual results to differ materially, including, but not limited to,
those factors described in the presentation and in the Company's filings with
the Securities and Exchange Commission. The Company disclaims any intention or
obligation to update or revise any financial or other projections or other
forward-looking statements, whether because of new information, future events or
otherwise.
The information in each of Item 2.02 and Item 7.01 of this Form 8-K and in the
press release attached as Exhibit 99.1 and the presentation attached as Exhibit
99.2 is being furnished and shall not be deemed "filed" for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or
otherwise subject to the liabilities of that Section. The information in each of
Item 2.02 and Item 7.01 of this Form 8-K and each of Exhibit 99.1 and Exhibit
99.2 shall not be incorporated by reference in any filing (whether made before
or after the date hereof) or any other document under the Securities Act of
1933, as amended, or the Exchange Act, except as expressly set forth by specific
reference in any such filing or document.
Item 9.01  Financial Statements and Exhibits.
(d)Exhibits
No.            Description
99.1             Press Release dated January 10, 2022
99.2             Investor Presentation
               Cover Page Interactive Data File--the cover page XBRL tags are embedded within
104            the Inline XBRL document.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses